Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Immutep Limited is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company operates within the biopharmaceutical and immuno-oncology industries, with its core scientific focus on modulating the Lymphocyte Activation Gene-3 (LAG-3) pathway to stimulate or suppress immune responses depending on disease context. Its primary value driver is its proprietary LAG-3 platform, which underpins multiple clinical and preclinical product candidates.
The company’s lead product candidate, eftilagimod alpha (efti), is an antigen-presenting cell activator designed to enhance immune responses in combination with other cancer therapies, particularly immune checkpoint inhibitors. Immutep’s strategy centers on partnering its assets with large pharmaceutical companies to accelerate development while retaining selective development rights. Founded in 1987 as Prima BioMed and rebranded as Immutep in 2014, the company evolved from early-stage immunology research into a focused LAG-3–centric biotechnology platform with multiple clinical programs.
Business Operations
Immutep generates value through the research, development, and clinical advancement of immunotherapy drug candidates rather than commercial product sales. Its operations are organized around its LAG-3-based technology platform, which supports several therapeutic approaches, including immune activation for oncology and immune suppression for autoimmune diseases. The company’s most advanced clinical asset, eftilagimod alpha, is being evaluated in multiple Phase II and Phase III clinical trials, including combination studies with approved PD-1 inhibitors.
Operationally, Immutep conducts research and development primarily through its wholly owned subsidiary Immutep S.A.S., which manages laboratory research, translational science, and clinical development activities. The company collaborates with academic institutions, clinical research organizations, and pharmaceutical partners to conduct trials and advance its pipeline. Revenue to date has primarily consisted of collaboration income, grants, and research tax incentives, rather than recurring commercial revenue.
Strategic Position & Investments
Immutep’s strategic direction is centered on establishing LAG-3 modulation as a differentiated and clinically validated approach in immunotherapy. A key growth initiative is advancing eftilagimod alpha toward late-stage development in oncology indications such as metastatic breast cancer and non-small cell lung cancer, often in combination with established checkpoint inhibitors. The company positions efti as a complementary immune activator rather than a competing checkpoint blocker, which it views as a strategic advantage in combination regimens.
Beyond efti, Immutep is investing in earlier-stage assets, including IMP761, a LAG-3 agonist aimed at autoimmune and inflammatory diseases, and IMP731, designed for antigen-specific immune tolerance. The company has historically entered into strategic collaborations and licensing discussions to share development risk while preserving upside, though no large-scale commercial acquisitions have been completed. Its portfolio reflects a deliberate balance between oncology-focused growth assets and longer-term autoimmune disease opportunities.
Geographic Footprint
Immutep is headquartered in Australia, with its corporate parent domiciled in Sydney and listed on both the Australian Securities Exchange and NASDAQ via American Depositary Shares. Its primary research and development activities are conducted in Europe, particularly in France, where its main operating subsidiary is based and where much of its scientific staff and laboratory infrastructure are located.
Clinically, the company has an international footprint, with trials conducted across North America, Europe, and parts of Asia-Pacific, reflecting its focus on global oncology markets. While Immutep does not maintain commercial operations in these regions, its clinical and regulatory activities provide it with exposure to major pharmaceutical markets and regulatory agencies worldwide.
Leadership & Governance
Immutep was founded by Dr. Thierry Hercend, whose early research contributed to the scientific foundation of the company’s immunology platform. The current leadership team emphasizes disciplined capital management, partnership-driven development, and scientific differentiation within competitive immunotherapy markets. Governance is structured to support a research-intensive organization with oversight from an experienced board and executive team.
Key executives include:
- Marc Voigt – Chief Executive Officer
- Dr. Frédéric Triebel – Chief Scientific Officer
- Dr. Andrew Hoy – Chief Medical Officer
- David Jenkins – Chief Financial Officer
The leadership team’s stated strategic vision centers on translating deep immunological expertise into clinically meaningful therapies while leveraging partnerships to maximize shareholder value and manage development risk.